- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 455/02 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
Patent holdings for IPC class C07D 455/02
Total number of patents in this class: 98
10-year publication summary
|
6
|
7
|
4
|
5
|
5
|
6
|
4
|
8
|
4
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3749 |
9 |
| Biosplice Therapeutics, Inc. | 171 |
5 |
| Merck Sharp & Dohme Corp. | 2191 |
4 |
| Takeda Pharmaceutical Company Limited | 2711 |
4 |
| Emergent Product Development Gaithersburg Inc. | 44 |
4 |
| Dice Alpha, Inc. | 18 |
4 |
| Novartis AG | 10741 |
3 |
| F. Hoffmann-La Roche AG | 7945 |
3 |
| The Trustees of Columbia University in the City of New York | 3578 |
3 |
| 55pharma Drug Discovery & Development AG | 3 |
3 |
| Rigel Pharmaceuticals, Inc. | 537 |
3 |
| Techfields Pharma Co., Ltd. | 30 |
3 |
| Bristol-myers Squibb Company | 4881 |
2 |
| Merck & Co., Inc. | 317 |
2 |
| Centre National de La Recherche Scientifique | 10465 |
2 |
| Incyte Corporation | 1026 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 830 |
2 |
| Universite Grenoble Alpes | 730 |
2 |
| The Procter & Gamble Company | 22045 |
1 |
| Pfizer Inc. | 3368 |
1 |
| Other owners | 36 |